Moscow, June 15: AstraZeneca announced on Tuesday that the clinical trial of its long-acting antibody cocktail has not provided evidence of effectiveness in protecting people exposed to the coronavirus.
The trial involved 1,121 adult participants who had been exposed to a person who tested positive for COVID-19 within eight days. The placebo group had 17 cases, while a group where participants were administered with AZD7442 – a combination of two different monoclonal antibodies – had 23. The company noted that the antibody cocktail lowered the risk of developing a symptomatic infection by 33%, which is not a statistically significant result.
“The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo,” AstraZeneca said in a statement. Pfizer, AstraZeneca COVID-19 Vaccines Highly Effective Against Delta Variant.
The company promised to publish the results from the trial in a peer-reviewed medical journal. AZD7442 is produced from two long-acting monoclonal antibodies acquired from plasma of convalescent COVID-19 patients.
(This is an unedited and auto-generated story from Syndicated News feed, Today News 24 Staff may not have modified or edited the content body)
//vdo (function(v,d,o,ai){ai=d.createElement('script');ai.defer=true;ai.async=true;ai.src=v.location.protocol+o;d.head.appendChild(ai);})(window, document, '//a.vdo.ai/core/latestly/vdo.ai.js');
//colombai try{ (function() { var cads = document.createElement("script"); cads.async = true; cads.type = "text/javascript"; cads.src = "https://static.clmbtech.com/ase/80185/3040/c1.js"; var node = document.getElementsByTagName("script")[0]; node.parentNode.insertBefore(cads, node); })(); }catch(e){}
} });